Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher Award

Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher Award🏆


Assistant Professor at Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
🎓

Joanna Jazowiecka-Rakus is an Assistant Professor with a strong focus on advancing cancer research through innovative oncolytic therapies. Her work at the Maria Skłodowska Memorial National Institute of Oncology in Gliwice, Poland, positions her as a leading expert in experimental cancer treatments. Dr. Jazowiecka-Rakus’s pioneering research in oncolytic virotherapy and nanocarrier drug delivery aims to address complex cancers like pancreatic adenocarcinoma, glioma, and melanoma. With a reputation for pushing boundaries in cancer treatment, she continues to make strides in developing therapies that offer new hope for patients with challenging diagnoses.

Professional Profile 

🎓 Education

Dr. Jazowiecka-Rakus holds a Master of Science in Biology from the Faculty of Biology, University of Silesia, Katowice, Poland (2001), followed by a Ph.D. in Medical Biology from the National Institute of Oncology, Warsaw, Poland (2007). In recognition of her exceptional contributions to cancer research, she earned a D.Sc. (habilitation) in Medical Sciences from the same institution. Her academic path reflects her dedication to enhancing cancer treatment through rigorous scientific training and specialization.

🏢 Work Experience

Throughout her career, Dr. Jazowiecka-Rakus has held esteemed research positions, including her current role as an Assistant Professor at the National Institute of Oncology. Her work has been instrumental in projects funded by prestigious institutions like the International Center for Genetic Engineering and Biotechnology and the National Science Center of Poland. Notably, her research covers a wide spectrum of experimental cancer therapies, including the use of myxoma viruses and mesenchymal stem cells to treat melanoma, ovarian cancer, and glioma. She has also forged valuable collaborations with global institutions, such as the Biodesign Institute at the University of Arizona, Tempe, USA.

🧬 Skills

Dr. Jazowiecka-Rakus brings a wealth of expertise in cancer treatment, highlighted by her skills in oncolytic virotherapy, cancer immunotherapy, and advanced drug delivery systems. Her work with oncolytic virotherapy focuses on developing viral therapies that specifically target and destroy cancer cells, offering a promising alternative to traditional cancer treatments. In cancer immunotherapy, she integrates immune-enhancing agents to create therapies for advanced cancers. Her pioneering methods for stem cell-based drug delivery use mesenchymal stem cells as carriers for oncolytic viruses, targeting tumor cells more effectively. Additionally, she has developed nanocarrier drug formulations that improve the delivery and efficacy of drugs in cancer treatment.

Awards and Honors 🏆

Dr. Jazowiecka-Rakus’s dedication to cancer research has earned her numerous accolades. Between 2017 and 2020, she was awarded a research grant by the International Center for Genetic Engineering and Biotechnology to study oncolytic melanoma therapy, underlining her impact in this vital area. Her scholarly contributions include 18 articles published in high-impact journals indexed in Web of Science and Scopus, reflecting her influence and recognition within the cancer research community. Her works have accumulated a citation index of over 431, showcasing the significant reach and impact of her research.

🌐 Memberships

Active in professional societies, Dr. Jazowiecka-Rakus is an auditor for the Association for the Support of Cancer Research in Gliwice, Poland, where she contributes to promoting research integrity and supporting advancements in cancer studies. She is also a member of the Polish Radiation Research Society based in Warsaw, where she engages with other professionals dedicated to improving cancer treatment and sharing knowledge within the field.

📚 Teaching Experience

As an Assistant Professor, Dr. Jazowiecka-Rakus is committed to educating and mentoring the next generation of cancer researchers at the National Institute of Oncology. Her teaching covers essential aspects of oncology and medical biology, with a particular focus on innovative treatment strategies in cancer research. Through her courses and mentoring, she guides students in understanding the complexities of cancer treatment, encouraging them to pursue research that makes a real-world impact.

🔬 Research Focus

Dr. Jazowiecka-Rakus’s research centers on developing experimental therapies for aggressive cancers. Her work includes the creation of oncolytic myxoma virus constructs, which use mesenchymal stem cells as carriers to deliver viral therapies specifically targeting cancers such as pancreatic adenocarcinoma and glioma. She has developed advanced blood-brain barrier crossing techniques to treat glioma through intra-arterial delivery, offering a new method to target brain tumors effectively. Additionally, her research on 3D models for cancer uses spheroid and organoid models to test therapies for disseminated ovarian cancer, pushing the boundaries of cancer treatment with innovative laboratory models that mimic real-world conditions. Dr. Jazowiecka-Rakus’s interdisciplinary approach highlights her dedication to advancing the field of cancer therapy and improving patient outcomes.

Conclusion 

In conclusion, Dr. Joanna Jazowiecka-Rakus exemplifies the qualities of an outstanding researcher through her innovative projects, significant contributions to cancer research, and a strong academic foundation. Her ongoing work and potential for future advancements make her a deserving candidate for the Best Researcher Award. Enhancing her publication record and pursuing patent opportunities would further solidify her standing as a leader in the field.

📚 Publilcation 

  • Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood–Brain Barrier and Treat Murine Glioma
  • Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
  • Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
  • Removal of Heavy Metal Ions from Wastewaters: An Application of Sodium Trithiocarbonate and Wastewater Toxicity Assessment
  • COVID-19 Autopsies: A Case Series from Poland
  • Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
  • Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses

 

Dr Alexander Chernov| neuro-oncology | Best Researcher Award

Dr Alexander Chernov| neuro-oncology | Best Researcher Award 🏆


DR at Institute of Experimental Medicine🎓

Dr. Alexander Nikolaevich Chernov is a PhD and Senior Researcher at the World-Class Research Centre “Center for Personalized Medicine” at the Institute of Experimental Medicine, Saint Petersburg, Russia 🧬. With an impressive portfolio of over 80 scientific papers, six patents, and ongoing collaborations with international institutions, Dr. Chernov has made significant contributions in the fields of neuroimmunooncology, glioblastoma research, and the study of nerve growth factors. In 2021, he defended his PhD thesis on the effects of nerve growth factor and immune peptides on brain tumor cells, and in 2022-2023, he completed a postdoctoral fellowship at Ben-Gurion University, Israel 🇮🇱.

 

Professional Profile 

Education 🎓

Dr. Chernov holds a PhD with expertise in neurobiology, focusing on brain tumors and chemotherapy. He has a solid foundation in biochemistry, serving as an assistant professor at Saint Petersburg State Pediatric Medical University 🎓.

Work Experience 🏢

Dr. Chernov’s extensive research includes working as a senior researcher at multiple prestigious institutions in Russia, including the D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology. He has also been involved in numerous consultancy and industry projects across nine different sectors.

Awards and Honors 🏆

Dr. Chernov has earned recognition for his exceptional work in brain tumor research, including the nomination for the Best Researcher Award for his article on glioblastoma sensitivity to antimicrobial peptides.

👨‍🏫 Teaching & Memberships🌍

Dr. Chernov is a dedicated educator, currently teaching biochemistry at Saint Petersburg State Pediatric Medical University. He is a member of the Belarusian Society of Physiologists, contributing to his international scientific community .

Research Focus 🔍

His main research areas include glioblastoma, nerve growth factors, chemotherapy, and antimicrobial peptides such as LL-37 and PG-1 🧠. Dr. Chernov’s groundbreaking work has shown how these peptides, in combination with chemotherapy drugs, can predict overall survival in patients with glioblastoma. His research has also demonstrated the effects of these combinations on the inhibition of glioma cell clonogenicity and migration.

Publications : 

 

  • “Cytotoxic effects of chemotherapeutic drugs and heterocyclic compounds at application on the cells of primary culture of neuroepithelium tumors”
    • Medicinal Chemistry, 2012
  • “Fourth generation phosphorus-containing dendrimers: prospective drug and gene delivery carrier”
    • Pharmaceutics, 2011
  • “Biological activity of silver-doped DLC films”
    • Diamond and Related Materials, 2009
  • “Analysis of the Spectrum of ACE2 Variation Suggests a Possible Influence of Rare and Common Variants on Susceptibility to COVID-19 and Severity of Outcome”
    • Frontiers in Genetics, 2020
  • “Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients”
    • Frontiers in Immunology, 2021
  • “The phenomenon of multidrug resistance in glioblastomas”
    • Hematology/Oncology and Stem Cell Therapy, 2021
  • “Genetic risk factors for the development of COVID-19 coronavirus infection”
    • Russian Journal of Genetics, 2021
  • “Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients”
    • Pharmaceutics, 2022
  • “Pathophysiological mechanisms of autism in children”
    • Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2020
  • “Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration”
    • Molecules, 2022